Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-3114
Feder-Mengus, C; Wyler, S; Hudolin, T; Ruszat, R; Bubendorf, L; Chiarugi, A; Pittelli, M; Weber, W; Bachmann, A; Gasser, T C; Sulser, T; Heberer, M; Spagnoli, G C; Provenzano, M (2008). High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. European Journal of Cancer, 44(15):2266-2275.
View at publisher
- Registered users only
Arginase 2, inducible- and endothelial-nitric-oxide synthase (iNOS and eNOS), indoleamine 2,3-dioxygenase (IDO) and TGF-beta, might impair immune functions in prostate cancer (PCA) patients. However, their expression was not comparatively analysed in PCA and benign prostatic hyperplasia (BPH). We evaluated the expression of these genes in PCA and BPH tissues. Seventy-six patients (42 BPH, 34 PCA) were enrolled. Arginase 2, eNOS and iNOS gene expression was similar in BPH and PCA tissues. TGF-beta1 gene expression was higher in BPH than in PCA tissues (p=0.035). IDO gene expression was more frequently detectable (p=0.00007) and quantitatively higher (p=0.00001) in PCA tissues than in BPH. IDO protein, expressed in endothelial cells from both BPH and PCA, was detectable in tumour cells in PCA showing evidence of high specific gene expression. In these patients, IDO gene expression correlated with kynurenine/tryptophan ratio in sera. Thus high expression of IDO gene is specifically detectable in PCA.
204 downloads since deposited on 11 Nov 2008
75 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Urological Clinic
04 Faculty of Medicine > University Hospital Zurich > Division of Surgical Research
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||11 Nov 2008 12:48|
|Last Modified:||19 Jul 2014 12:43|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page